

A BETTER APPROACH FOR BETTER CLINICAL TRIALS

Breast cancer affects more women worldwide than any other cancer. Despite its prevalence, studying and improving treatment is extremely complex. Oncology studies often involve multiple cohorts, tumor types, scattered sites, and expensive medications. More importantly, breast cancer patients face debilitating symptoms that can make participation in studies difficult. That's where Signant Health's SmartSignals™ evidence generation solutions can help.

IMPLEMENT eCOA IN JUST 8 WEEKS

With over 20 years of experience supporting breast cancer trials, we created a pre-configured eCOA solution that incorporates pre-validated library instruments, scientific design best practices, oncology-specific features as well as our unrivaled global logistics and support.

It's 33% faster than other eCOA options and will reduce your costs by 20%.

PLACE THE PATIENT FIRST

Our patient-focused approach is embedded in everything from the software to the eCOA instruments' overall designs. For example, thoughtfully migrating instrument layouts to electronic formats to ensure ease of use, such as larger, well-spaced buttons compensate for treatment-related finger numbness.

GAIN RICHER INSIGHTS

With our sensors and wearables, you can collect objective data on sleep and activity patterns, for enhanced insight into the post-treatment recovery associated with each treatment cycle. Pair with our eCOA for a continuous, real-time view of each patient's health status.

At Signant Health, our suite of SmartSignals™ solutions was designed specifically to meet the needs of breast cancer sponsors, sites, and patients alike. Make sure your breast cancer findings are reliable with today's latest technology.

SIMPLIFY THE CONSENT PROCESS

Signant Health's eConsent uses engaging multimedia to convey complex information and allows patients to flag sections they have questions on. The solution also handles the multiple consents and protocol amendments common in breast cancer trials, limiting the risk of inspection findings.

OPTIMIZE SUPPLY MANAGEMENT

Our RTSM solution uses proprietary algorithms to optimize drug supplies for the different, complex study designs associated with breast cancer trials, and applies randomization adaptations seamlessly.

DIGITALIZE THE ENTIRE PROCESS

While all of our solutions can be used as standalone tools, they seamlessly integrate with one another to further enhance the accuracy and efficiency of your breast cancer study.

COMMON LIBRARY MEASURES USED IN BREAST CANCER

- EORTC QLQ-C30 and QLQ-BR23
- FACT-G, Fatigue
- PROMIS fatigue
- PHQ-9
- HADS
- PRO-CTCAE
- SF-36 and EQ-5D


ASK US FOR A COMPLETE LIST.

SIGNANT'S BREAST CANCER EXPERIENCE

Phases



48
Trials




61
Languages



71
Countries



23,000+
Patients



5,830
Sites

SMARTSIGNALS SOLUTIONS

The SmartSignals solutions can be used individually or integrated together for a seamless, end-to-end digital experience.

Pre-configured eCOA




RTSM



Activity & sleep monitoring



eConsent



DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



MEET THE EXPERTS